Recent advances in the treatment of adult T‐cell leukemia‐lymphomas

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|4|344-351

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.4, 2015-04, pp. : 344-351

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advanced human T‐cell leukemia virus type 1 carriers and early‐stage indolent adult T‐cell leukemia‐lymphoma are indistinguishable based on CADM1 positivity in flow cytometry

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 598-603

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T‐cell leukemia/lymphoma

By  

Cancer Science, Vol. 106, Iss. 9, 2015-09 ,pp. : 1219-1223

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T‐cell leukemia

By  

Cancer Science, Vol. 109, Iss. 1, 2018-01 ,pp. : 103-111

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cadmium‐coordinated supramolecule suppresses tumor growth of T‐cell leukemia in mice

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 635-641

John Wiley & Sons Inc

Access to resources Recommend Favorite